No articles found for this sector...

================================================================================

[TITLE]Congress Asset Management Co. Sells 3,480 Shares of Acadia Healthcare Company, Inc. $ACHC:
[TEXT]
Congress Asset Management Co. trimmed its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC – Free Report) by 2.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 170,037 shares of the company’s stock after selling 3,480 shares during the period. Congress Asset Management Co. owned
[Source link]: https://www.etfdailynews.com/2025/09/28/congress-asset-management-co-sells-3480-shares-of-acadia-healthcare-company-inc-achc/


[TITLE]CX Institutional Sells 2,378 Shares of iShares U.S. Healthcare Providers ETF $IHF:
[TEXT]
CX Institutional cut its stake in iShares U.S. Healthcare Providers ETF (NYSEARCA:IHF – Free Report) by 26.2% in the second quarter, Holdings Channel.com reports. The firm owned 6,702 shares of the company’s stock after selling 2,378 shares during the period. CX Institutional’s holdings in iShares U.S. Healthcare Providers ETF were worth $326,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Jones Financial Companies Lllp boosted its holdings in iShares U.S. Healthcare Providers ETF by 615.9% in the 1st quarter. Jones Financial Companies Lllp now owns 175,412 shares of the company’s stock valued at $9,262,000 after purchasing an additional 150,909 shares during the period. Federation des caisses Desjardins du Quebec boosted its holdings in iShares U.S. Healthcare Providers ETF by 11.9% in the 1st quarter. Federation des caisses Desjardins du Quebec now owns 152,896 shares of the company’s stock valued at $8,073,000 after purchasing an additional 16,212 shares during the period. Cetera Investment Advisers boosted its holdings in iShares U.S. Healthcare Providers ETF by 4.9% in the 1st quarter. Cetera Investment Advisers now owns 125,474 shares of the company’s stock valued at $6,625,000 after purchasing an additional 5,876 shares during the period. Goldman Sachs Group Inc. boosted its holdings in iShares U.S. Healthcare Providers ETF by 6.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 124,536 shares of the company’s stock valued at $6,576,000 after purchasing an additional 7,393 shares during the period. Finally, Avantax Advisory Services Inc. lifted its holdings in shares of iShares U.S. Healthcare Providers ETF by 13.1% during the 1st quarter. Avantax Advisory Services Inc. now owns 78,704 shares of the company’s stock worth $4,156,000 after acquiring an additional 9,143 shares during the period.

Get iShares U.S. Healthcare Providers ETF alerts:

iShares U.S. Healthcare Providers ETF Stock Performance

NYSEARCA:IHF opened at $49.10 on Friday. The company has a 50-day moving average of $45.64 and a 200-day moving average of $47.92. The company has a market capitalization of $694.77 million, a price-to-earnings ratio of 15.41 and a beta of 0.81. iShares U.S. Healthcare Providers ETF has a 52 week low of $40.57 and a 52 week high of $57.25.

About iShares U.S. Healthcare Providers ETF

The iShares U.S. Healthcare Providers ETF (IHF) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a cap-weighted index of US companies that provide healthcare services. IHF was launched on May 1, 2006 and is managed by BlackRock.

Featured Stories

Want to see what other hedge funds are holding IHF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Healthcare Providers ETF (NYSEARCA:IHF – Free Report).

Receive News & Ratings for iShares U.S. Healthcare Providers ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Healthcare Providers ETF and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/28/cx-institutional-sells-2378-shares-of-ishares-u-s-healthcare-providers-etf-ihf-2/


[TITLE]Wealth Enhancement Advisory Services LLC Grows Stake in STERIS plc $STE:
[TEXT]
Wealth Enhancement Advisory Services LLC lifted its position in STERIS plc (NYSE:STE – Free Report) by 29.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,493 shares of the medical equipment provider’s stock after buying an additional 2,415 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in STERIS were worth $2,493,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of STE. QRG Capital Management Inc. lifted its position in STERIS by 122.5% during the first quarter. QRG Capital Management Inc. now owns 2,832 shares of the medical equipment provider’s stock valued at $642,000 after purchasing an additional 1,559 shares in the last quarter. Foresight Group Ltd Liability Partnership purchased a new position in STERIS during the first quarter valued at $25,958,000. Allianz Asset Management GmbH lifted its position in STERIS by 31.9% during the first quarter. Allianz Asset Management GmbH now owns 102,488 shares of the medical equipment provider’s stock valued at $23,229,000 after purchasing an additional 24,809 shares in the last quarter. Ascent Group LLC purchased a new position in STERIS during the first quarter valued at $261,000. Finally, Dynamic Advisor Solutions LLC lifted its position in STERIS by 23.6% during the first quarter. Dynamic Advisor Solutions LLC now owns 1,203 shares of the medical equipment provider’s stock valued at $273,000 after purchasing an additional 230 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Get STERIS alerts:

Insider Transactions at STERIS

In related news, VP Renato Tamaro sold 3,204 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total value of $798,564.96. Following the transaction, the vice president directly owned 7,221 shares of the company’s stock, valued at $1,799,762.04. This represents a 30.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mohsen Sohi sold 4,110 shares of the company’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.96, for a total transaction of $994,455.60. Following the completion of the sale, the director directly owned 22,361 shares in the company, valued at approximately $5,410,467.56. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,709 shares of company stock valued at $4,546,940 in the last quarter. Insiders own 1.07% of the company’s stock.

STERIS Stock Performance

Shares of STE opened at $248.82 on Friday. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27. The stock has a fifty day moving average price of $241.31 and a 200-day moving average price of $234.68. STERIS plc has a 12 month low of $200.98 and a 12 month high of $253.00. The firm has a market cap of $24.51 billion, a PE ratio of 38.10 and a beta of 0.95.

STERIS (NYSE:STE – Get Free Report) last released its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.02. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The firm had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the firm earned $2.03 EPS. The firm’s revenue was up 8.8% on a year-over-year basis. Equities research analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 26th. Investors of record on Thursday, September 4th were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, September 4th. This is a positive change from STERIS’s previous quarterly dividend of $0.57. STERIS’s payout ratio is currently 38.59%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Morgan Stanley lifted their target price on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Finally, KeyCorp boosted their price objective on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $273.50.

Read Our Latest Research Report on STE

STERIS Company Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

See Also

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/28/wealth-enhancement-advisory-services-llc-grows-stake-in-steris-plc-ste/


[TITLE]Top Biotech Stocks To Watch Today – September 25th:
[TEXT]
PepGen, Danaher, Vertex Pharmaceuticals, Evaxion A/S, Recursion Pharmaceuticals, argenex, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies focused on researching, developing and commercializing medical therapies, diagnostics and other health-related technologies based on biological processes. They often carry higher growth potential due to breakthrough treatments in areas like gene therapy and personalized medicine, but also exhibit greater volatility and risk tied to clinical trial outcomes and regulatory approvals. Investors in biotech stocks typically seek exposure to the life-science sector’s innovation-driven upside while managing the uncertainty inherent in drug development. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Get alerts:

PepGen (PEPG)

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX

Evaxion A/S (EVAX)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.

Read Our Latest Research Report on EVAX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Read Our Latest Research Report on RXRX

argenex (ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Read Our Latest Research Report on ARGX

United Therapeutics (UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read Our Latest Research Report on UTHR

Featured Stories
[Source link]: https://www.etfdailynews.com/2025/09/28/top-biotech-stocks-to-watch-today-september-25th/


===== Company info for companies mentioned in news =====

Company name: acadia healthcare company
name: acadia healthcare company
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=acadia+healthcare+company&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: ishares u.s. healthcare providers etf
name: ishares u.s. healthcare providers etf
symbol: None
note: non-listable or generic entity
------------------------------------------------------------------

Company name: pepgen
symbol: PEPG
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759152142
name: pepgen
------------------------------------------------------------------

Company name: steris plc
symbol: STE
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759152143
name: steris plc
------------------------------------------------------------------

================================================================================

[TITLE]Only Sun Pharma exposed to some headline risk, but with limited earnings impact:
[TEXT]
The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts.

Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (
[Source link]: https://www.thehindubusinessline.com/economy/only-sun-pharma-exposed-to-some-headline-risk-but-with-limited-earnings-impact/article70104680.ece


[TITLE]US Tariffs: Only Sun Pharma exposed to some headline risk, but with limited earnings impact:
[TEXT]
Live Events

as a Reliable and Trusted News Source Addas a Reliable and Trusted News Source Add Now!

(You can now subscribe to our

(You can now subscribe to our Economic Times WhatsApp channel

The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts.Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (
[Source link]: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-tariffs-only-sun-pharma-exposed-to-some-headline-risk-but-with-limited-earnings-impact/articleshow/124191956.cms


===== Company info for companies mentioned in news =====

Company name: sun pharma
name: sun pharma
symbol: None
note: no reliable listing found
------------------------------------------------------------------

================================================================================

[TITLE]Spyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from Analysts at Deutsche Bank Aktiengesellschaft:
[TEXT]
Deutsche Bank Aktiengesellschaft initiated coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) in a research note published on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $43.00 price target on the stock.

A number of other equities research analysts have also commented on SYRE. Wedbush reissued an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 20th. Finally, BTIG Research reissued a “buy” rating and set a $70.00 price objective on shares of Spyre Therapeutics in a report on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, Spyre Therapeutics currently has an average rating of “Buy” and an average target price of $54.29.

Get Spyre Therapeutics alerts:

Read Our Latest Research Report on SYRE

Spyre Therapeutics Stock Performance

SYRE opened at $16.24 on Friday. The firm’s 50-day simple moving average is $16.40 and its 200-day simple moving average is $15.73. Spyre Therapeutics has a twelve month low of $10.91 and a twelve month high of $40.26. The firm has a market cap of $980.90 million, a price-to-earnings ratio of -4.78 and a beta of 2.87.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.24. As a group, sell-side analysts anticipate that Spyre Therapeutics will post -4.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Scott L. Burrows sold 18,428 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $16.26, for a total transaction of $299,639.28. Following the transaction, the chief financial officer directly owned 97,994 shares in the company, valued at approximately $1,593,382.44. The trade was a 15.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 15.43% of the company’s stock.

Hedge Funds Weigh In On Spyre Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Paradigm Biocapital Advisors LP boosted its position in Spyre Therapeutics by 39.3% during the first quarter. Paradigm Biocapital Advisors LP now owns 2,127,205 shares of the company’s stock worth $34,322,000 after purchasing an additional 600,000 shares during the period. Millennium Management LLC bought a new stake in shares of Spyre Therapeutics in the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/27/spyre-therapeutics-nasdaqsyre-earns-buy-rating-from-analysts-at-deutsche-bank-aktiengesellschaft/


[TITLE]The Goldman Sachs Group Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock:
[TEXT]
uniQure (NASDAQ:QURE – Get Free Report) had its price target lifted by analysts at The Goldman Sachs Group from $13.00 to $56.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 3.11% from the company’s previous close.

Other research analysts also recently issued reports
[Source link]: https://www.etfdailynews.com/2025/09/27/the-goldman-sachs-group-forecasts-strong-price-appreciation-for-uniqure-nasdaqqure-stock/


[TITLE]argenex SE (NASDAQ:ARGX) Receives $789.20 Average Target Price from Brokerages:
[TEXT]
Shares of argenex SE (NASDAQ:ARGX – Get Free Report) have earned a consensus recommendation of “Buy” from the twenty-four research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, twenty have given a buy rating and three have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $789.20.

A number of equities research analysts have issued reports on ARGX shares. HC Wainwright upped their price objective on argenex from $720.00 to $774.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Piper Sandler upped their price objective on argenex from $750.00 to $820.00 and gave the company an “overweight” rating in a research report on Tuesday, August 26th. JPMorgan Chase & Co. upped their price objective on argenex from $775.00 to $830.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Wells Fargo & Company upped their price objective on argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research report on Thursday, July 31st. Finally, Bank of America upped their price objective on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd.

Get argenex alerts:

View Our Latest Research Report on argenex

Institutional Inflows and Outflows

argenex Trading Up 0.1%

Hedge funds have recently modified their holdings of the business. Rakuten Securities Inc. grew its stake in shares of argenex by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock valued at $36,000 after buying an additional 22 shares during the last quarter. WPG Advisers LLC bought a new position in argenex in the first quarter worth approximately $37,000. Golden State Wealth Management LLC bought a new position in argenex in the first quarter worth approximately $44,000. Brooklyn Investment Group grew its stake in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 38 shares in the last quarter. Finally, MAI Capital Management grew its stake in argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after purchasing an additional 78 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

NASDAQ:ARGX opened at $711.62 on Wednesday. The company has a market capitalization of $43.55 billion, a P/E ratio of 36.49, a P/E/G ratio of 0.78 and a beta of 0.41. argenex has a 12 month low of $510.05 and a 12 month high of $779.03. The business’s 50-day moving average is $684.59 and its 200 day moving average is $615.47.

argenex (NASDAQ:ARGX – Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.90. The company had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. On average, research analysts forecast that argenex will post 3.13 earnings per share for the current year.

argenex Company Profile

(Get Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Recommended Stories

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/27/argenex-se-nasdaqargx-receives-789-20-average-target-price-from-brokerages/


[TITLE]uniQure (NASDAQ:QURE) Shares Gap Up Following Analyst Upgrade:
[TEXT]
uniQure N.V. (NASDAQ:QURE – Get Free Report)’s share price gapped up prior to trading on Thursday after The Goldman Sachs Group raised their price target on the stock from $13.00 to $56.00. The stock had previously closed at $47.50, but opened at $50.43. The Goldman Sachs Group currently has a neutral rating on the stock. uniQure shares last traded at $50.29, with a volume of 5,532,913 shares changing hands.

QURE has been the topic of a number of other research reports. Chardan Capital increased their price target on uniQure from $35.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada reiterated an “outperform” rating on shares of uniQure in a research note on Wednesday. Wells Fargo & Company lifted their target price on uniQure from $30.00 to $65.00 and gave the company an “overweight” rating in a research note on Thursday. Stifel Nicolaus lifted their target price on uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Leerink Partners lifted their target price on uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $67.17.

Get uniQure alerts:

Get Our Latest Stock Report on QURE

Insider Activity at uniQure

Institutional Trading of uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 226,316 shares of the firm’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the sale, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last quarter, insiders have sold 244,316 shares of company stock valued at $10,328,181. 4.79% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in QURE. Jefferies Financial Group Inc. acquired a new stake in shares of uniQure in the second quarter worth approximately $29,217,000. Vestal Point Capital LP lifted its position in uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after buying an additional 1,767,572 shares in the last quarter. JPMorgan Chase & Co. lifted its position in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after buying an additional 1,491,486 shares in the last quarter. Sofinnova Investments Inc. lifted its position in uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after buying an additional 1,012,585 shares in the last quarter. Finally, Aberdeen Group plc lifted its position in uniQure by 46.8% during the first quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company’s stock worth $23,485,000 after buying an additional 706,216 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Performance

The stock has a market cap of $2.98 billion, a PE ratio of -13.85 and a beta of 0.14. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock has a 50-day moving average of $17.44 and a 200 day moving average of $14.89.

uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. Equities analysts predict that uniQure N.V. will post -3.75 EPS for the current fiscal year.

uniQure Company Profile

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Recommended Stories

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/27/uniqure-nasdaqqure-shares-gap-up-following-analyst-upgrade/


===== Company info for companies mentioned in news =====

Company name: argenex se
name: argenex se
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: spyre therapeutics
symbol: SYRE
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759152149
name: spyre therapeutics
------------------------------------------------------------------

Company name: uniqure
symbol: QURE
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759152150
name: uniqure
------------------------------------------------------------------

================================================================================

[TITLE]Wealth Enhancement Advisory Services LLC Grows Stake in STERIS plc $STE:
[TEXT]
Wealth Enhancement Advisory Services LLC lifted its position in STERIS plc (NYSE:STE – Free Report) by 29.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,493 shares of the medical equipment provider’s stock after buying an additional 2,415 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in STERIS were worth $2,493,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of STE. QRG Capital Management Inc. lifted its position in STERIS by 122.5% during the first quarter. QRG Capital Management Inc. now owns 2,832 shares of the medical equipment provider’s stock valued at $642,000 after purchasing an additional 1,559 shares in the last quarter. Foresight Group Ltd Liability Partnership purchased a new position in STERIS during the first quarter valued at $25,958,000. Allianz Asset Management GmbH lifted its position in STERIS by 31.9% during the first quarter. Allianz Asset Management GmbH now owns 102,488 shares of the medical equipment provider’s stock valued at $23,229,000 after purchasing an additional 24,809 shares in the last quarter. Ascent Group LLC purchased a new position in STERIS during the first quarter valued at $261,000. Finally, Dynamic Advisor Solutions LLC lifted its position in STERIS by 23.6% during the first quarter. Dynamic Advisor Solutions LLC now owns 1,203 shares of the medical equipment provider’s stock valued at $273,000 after purchasing an additional 230 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Get STERIS alerts:

Insider Transactions at STERIS

In related news, VP Renato Tamaro sold 3,204 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total value of $798,564.96. Following the transaction, the vice president directly owned 7,221 shares of the company’s stock, valued at $1,799,762.04. This represents a 30.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mohsen Sohi sold 4,110 shares of the company’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.96, for a total transaction of $994,455.60. Following the completion of the sale, the director directly owned 22,361 shares in the company, valued at approximately $5,410,467.56. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,709 shares of company stock valued at $4,546,940 in the last quarter. Insiders own 1.07% of the company’s stock.

STERIS Stock Performance

Shares of STE opened at $248.82 on Friday. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27. The stock has a fifty day moving average price of $241.31 and a 200-day moving average price of $234.68. STERIS plc has a 12 month low of $200.98 and a 12 month high of $253.00. The firm has a market cap of $24.51 billion, a PE ratio of 38.10 and a beta of 0.95.

STERIS (NYSE:STE – Get Free Report) last released its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.02. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The firm had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the firm earned $2.03 EPS. The firm’s revenue was up 8.8% on a year-over-year basis. Equities research analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 26th. Investors of record on Thursday, September 4th were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, September 4th. This is a positive change from STERIS’s previous quarterly dividend of $0.57. STERIS’s payout ratio is currently 38.59%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Morgan Stanley lifted their target price on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Finally, KeyCorp boosted their price objective on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $273.50.

Read Our Latest Research Report on STE

STERIS Company Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

See Also

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/28/wealth-enhancement-advisory-services-llc-grows-stake-in-steris-plc-ste/


[TITLE]CX Institutional Sells 2,378 Shares of iShares U.S. Healthcare Providers ETF $IHF:
[TEXT]
CX Institutional cut its stake in iShares U.S. Healthcare Providers ETF (NYSEARCA:IHF – Free Report) by 26.2% in the second quarter, Holdings Channel.com reports. The firm owned 6,702 shares of the company’s stock after selling 2,378 shares during the period. CX Institutional’s holdings in iShares U.S. Healthcare Providers ETF were worth $326,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Jones Financial Companies Lllp boosted its holdings in iShares U.S. Healthcare Providers ETF by 615.9% in the 1st quarter. Jones Financial Companies Lllp now owns 175,412 shares of the company’s stock valued at $9,262,000 after purchasing an additional 150,909 shares during the period. Federation des caisses Desjardins du Quebec boosted its holdings in iShares U.S. Healthcare Providers ETF by 11.9% in the 1st quarter. Federation des caisses Desjardins du Quebec now owns 152,896 shares of the company’s stock valued at $8,073,000 after purchasing an additional 16,212 shares during the period. Cetera Investment Advisers boosted its holdings in iShares U.S. Healthcare Providers ETF by 4.9% in the 1st quarter. Cetera Investment Advisers now owns 125,474 shares of the company’s stock valued at $6,625,000 after purchasing an additional 5,876 shares during the period. Goldman Sachs Group Inc. boosted its holdings in iShares U.S. Healthcare Providers ETF by 6.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 124,536 shares of the company’s stock valued at $6,576,000 after purchasing an additional 7,393 shares during the period. Finally, Avantax Advisory Services Inc. lifted its holdings in shares of iShares U.S. Healthcare Providers ETF by 13.1% during the 1st quarter. Avantax Advisory Services Inc. now owns 78,704 shares of the company’s stock worth $4,156,000 after acquiring an additional 9,143 shares during the period.

Get iShares U.S. Healthcare Providers ETF alerts:

iShares U.S. Healthcare Providers ETF Stock Performance

NYSEARCA:IHF opened at $49.10 on Friday. The company has a 50-day moving average of $45.64 and a 200-day moving average of $47.92. The company has a market capitalization of $694.77 million, a price-to-earnings ratio of 15.41 and a beta of 0.81. iShares U.S. Healthcare Providers ETF has a 52 week low of $40.57 and a 52 week high of $57.25.

About iShares U.S. Healthcare Providers ETF

The iShares U.S. Healthcare Providers ETF (IHF) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a cap-weighted index of US companies that provide healthcare services. IHF was launched on May 1, 2006 and is managed by BlackRock.

Featured Stories

Want to see what other hedge funds are holding IHF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Healthcare Providers ETF (NYSEARCA:IHF – Free Report).

Receive News & Ratings for iShares U.S. Healthcare Providers ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Healthcare Providers ETF and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/28/cx-institutional-sells-2378-shares-of-ishares-u-s-healthcare-providers-etf-ihf-2/


[TITLE]Contrasting West Pharmaceutical Services (NYSE:WST) & Cardinal Health (NYSE:CAH):
[TEXT]
West Pharmaceutical Services (NYSE:WST – Get Free Report) and Cardinal Health (NYSE:CAH – Get Free Report) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 87.2% of Cardinal Health shares are owned by institutional investors. 0.5% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 0.1% of Cardinal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Get West Pharmaceutical Services alerts:

Dividends

West Pharmaceutical Services pays an annual dividend of $0.84 per share and has a dividend yield of 0.3%. Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 1.3%. West Pharmaceutical Services pays out 12.6% of its earnings in the form of a dividend. Cardinal Health pays out 31.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score West Pharmaceutical Services 0 3 7 2 2.92 Cardinal Health 0 3 11 0 2.79

This is a breakdown of recent recommendations and price targets for West Pharmaceutical Services and Cardinal Health, as provided by MarketBeat.

West Pharmaceutical Services presently has a consensus target price of $318.56, indicating a potential upside of 21.60%. Cardinal Health has a consensus target price of $165.93, indicating a potential upside of 7.86%. Given West Pharmaceutical Services’ stronger consensus rating and higher possible upside, analysts plainly believe West Pharmaceutical Services is more favorable than Cardinal Health.

Earnings & Valuation

This table compares West Pharmaceutical Services and Cardinal Health”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio West Pharmaceutical Services $2.89 billion 6.51 $492.70 million $6.68 39.22 Cardinal Health $222.58 billion 0.16 $1.56 billion $6.45 23.85

Cardinal Health has higher revenue and earnings than West Pharmaceutical Services. Cardinal Health is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares West Pharmaceutical Services and Cardinal Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets West Pharmaceutical Services 16.48% 18.43% 13.67% Cardinal Health 0.70% -74.45% 4.14%

Risk and Volatility

West Pharmaceutical Services has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Cardinal Health on 13 of the 18 factors compared between the two stocks.
[Source link]: https://www.etfdailynews.com/2025/09/28/contrasting-west-pharmaceutical-services-nysewst-cardinal-health-nysecah/


[TITLE]Top Biotech Stocks To Watch Today – September 25th:
[TEXT]
PepGen, Danaher, Vertex Pharmaceuticals, Evaxion A/S, Recursion Pharmaceuticals, argenex, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies focused on researching, developing and commercializing medical therapies, diagnostics and other health-related technologies based on biological processes. They often carry higher growth potential due to breakthrough treatments in areas like gene therapy and personalized medicine, but also exhibit greater volatility and risk tied to clinical trial outcomes and regulatory approvals. Investors in biotech stocks typically seek exposure to the life-science sector’s innovation-driven upside while managing the uncertainty inherent in drug development. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Get alerts:

PepGen (PEPG)

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX

Evaxion A/S (EVAX)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.

Read Our Latest Research Report on EVAX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Read Our Latest Research Report on RXRX

argenex (ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Read Our Latest Research Report on ARGX

United Therapeutics (UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read Our Latest Research Report on UTHR

Featured Stories
[Source link]: https://www.etfdailynews.com/2025/09/28/top-biotech-stocks-to-watch-today-september-25th/


===== Company info for companies mentioned in news =====

Company name: cardinal health
symbol: CAH
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759152152
name: cardinal health
------------------------------------------------------------------

Company name: ishares
name: ishares
symbol: None
note: non-listable or generic entity
------------------------------------------------------------------

Company name: steris
symbol: STE
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759152152
name: steris
------------------------------------------------------------------

Company name: west pharmaceutical services
name: west pharmaceutical services
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=west+pharmaceutical+services&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

